## Nicola Dalbeth, Fracp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9399081/publications.pdf

Version: 2024-02-01

452 papers

19,492 citations

65 h-index 19690

g-index

470 all docs

470 docs citations

times ranked

470

12346 citing authors

#	Article	IF	CITATIONS
1	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 2012, 64, 1431-1446.	1.5	1,268
2	Gout. Lancet, The, 2016, 388, 2039-2052.	6.3	774
3	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care and Research, 2012, 64, 1447-1461.	1.5	598
4	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1789-1798.	0.5	545
5	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care and Research, 2020, 72, 744-760.	1.5	420
6	Gout. Lancet, The, 2021, 397, 1843-1855.	6.3	418
7	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2557-2568.	2.9	393
8	Gout. Nature Reviews Disease Primers, 2019, 5, 69.	18.1	326
9	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis and Rheumatology, 2020, 72, 879-895.	2.9	302
10	Mechanism of Action of Colchicine in the Treatment of Gout. Clinical Therapeutics, 2014, 36, 1465-1479.	1.1	285
11	Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 2020, 382, 2504-2513.	13.9	281
12	CD56bright NK Cells Are Enriched at Inflammatory Sites and Can Engage with Monocytes in a Reciprocal Program of Activation. Journal of Immunology, 2004, 173, 6418-6426.	0.4	263
13	Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis and Rheumatism, 2012, 64, 2529-2536.	6.7	230
14	Cellular characterization of the gouty tophus: A quantitative analysis. Arthritis and Rheumatism, 2010, 62, 1549-1556.	6.7	204
15	A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis and Rheumatism, 2002, 46, 1763-1772.	6.7	188
16	An update on the genetics of hyperuricaemia and gout. Nature Reviews Rheumatology, 2018, 14, 341-353.	3.5	186
17	Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Annals of the Rheumatic Diseases, 2015, 74, 908-911.	0.5	184
18	A Review of Uric Acid, Crystal Deposition Disease, and Gout. Advances in Therapy, 2015, 32, 31-41.	1.3	184

#	Article	IF	Citations
19	National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology, 2012, 51, 901-909.	0.9	167
20	Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Journal of Rheumatology, 2006, 33, 1646-50.	1.0	160
21	Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Annals of the Rheumatic Diseases, 2009, 68, 1290-1295.	0.5	159
22	Outcome Domains for Studies of Acute and Chronic Gout. Journal of Rheumatology, 2009, 36, 2342-2345.	1.0	147
23	Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1868-1874.	0.5	145
24	The genetic basis of hyperuricaemia and gout. Joint Bone Spine, 2011, 78, 35-40.	0.8	143
25	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group. Journal of Rheumatology, 2015, 42, 2168-2171.	1.0	142
26	Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ: British Medical Journal, 2018, 363, k3951.	2.4	139
27	Allopurinol Dosing in Renal Impairment: Walking the Tightrope Between Adequate Urate Lowering and Adverse Events. Seminars in Dialysis, 2007, 20, 391-395.	0.7	133
28	The Experience and Impact of Living With Gout. Journal of Clinical Rheumatology, 2011, 17, 1-6.	0.5	133
29	Enhanced osteoclastogenesis in patients with tophaceous gout: Urate crystals promote osteoclast development through interactions with stromal cells. Arthritis and Rheumatism, 2008, 58, 1854-1865.	6.7	132
30	Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Annals of the Rheumatic Diseases, 2018, 77, 1048-1052.	0.5	131
31	Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis and Rheumatology, 2017, 69, 1903-1913.	2.9	124
32	Hyperuricaemia and gout: time for a new staging system?. Annals of the Rheumatic Diseases, 2014, 73, 1598-1600.	0.5	118
33	Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Annals of the Rheumatic Diseases, 2009, 68, 279-282.	0.5	114
34	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Annals of the Rheumatic Diseases, 2017, 76, 869-877.	0.5	114
35	Tendon involvement in the feet of patients with gout: a dual-energy CT study. Annals of the Rheumatic Diseases, 2013, 72, 1545-1548.	0.5	113
36	A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 2017, 76, 1522-1528.	0.5	107

#	Article	IF	CITATIONS
37	Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Research and Therapy, 2020, 22, 28.	1.6	104
38	Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout. Arthritis Care and Research, 2015, 67, 1304-1315.	1.5	101
39	A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not MÄori, case and control sample sets. Human Molecular Genetics, 2010, 19, 4813-4819.	1.4	100
40	Mouse models for human hyperuricaemia: a critical review. Nature Reviews Rheumatology, 2019, 15, 413-426.	3.5	99
41	Role of the urate transporter <i>SLC2A9</i> gene in susceptibility to gout in New Zealand MÄori, Pacific Island, and Caucasian case–control sample sets. Arthritis and Rheumatism, 2009, 60, 3485-3492.	6.7	98
42	Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care and Research, 2011, 63, 1605-1612.	1.5	97
43	The Gouty Tophus: a Review. Current Rheumatology Reports, 2015, 17, 19.	2.1	97
44	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis and Rheumatology, 2017, 69, 429-438.	2.9	93
45	Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskeletal Disorders, 2015, 16, 296.	0.8	91
46	Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Annals of the Rheumatic Diseases, 2010, 69, 1677-1682.	0.5	90
47	Developing a provisional definition of flare in patients with established gout. Arthritis and Rheumatism, 2012, 64, 1508-1517.	6.7	90
48	Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology, 2017, 56, 2170-2178.	0.9	90
49	Validation of a radiographic damage index in chronic gout. Arthritis and Rheumatism, 2007, 57, 1067-1073.	6.7	88
50	Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Research and Therapy, 2010, 12, R164.	1.6	87
51	New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis and Rheumatology, 2018, 70, 1702-1709.	2.9	86
52	Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Annals of the Rheumatic Diseases, 2012, 71, 929-934.	0.5	83
53	An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Seminars in Arthritis and Rheumatism, 2015, 45, 174-183.	1.6	82
54	Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Annals of the Rheumatic Diseases, 2011, 70, 597-604.	0.5	81

#	Article	IF	Citations
55	An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. Journal of Rheumatology, 2015, 42, 1702-1707.	1.0	79
56	Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney International, 2014, 85, 344-351.	2.6	78
57	Sugar-sweetened beverage consumption: a risk factor for prevalent gout with <i>SLC2A9</i> genotype-specific effects on serum urate and risk of gout. Annals of the Rheumatic Diseases, 2014, 73, 2101-2106.	0.5	77
58	Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Annals of the Rheumatic Diseases, 2011, 70, 1684-1691.	0.5	75
59	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nature Reviews Rheumatology, 2017, 13, 561-568.	3.5	74
60	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	1.5	73
61	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.5	72
62	Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Annals of the Rheumatic Diseases, 2014, 73, 797-802.	0.5	71
63	Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open, 2015, 1, e000075-e000075.	1.8	71
64	Effects of Febuxostat in Early Gout. Arthritis and Rheumatology, 2017, 69, 2386-2395.	2.9	71
65	The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nature Communications, 2020, 11, 2767.	5.8	71
66	Imaging in gout - What can we learn from MRI, CT, DECT and US?. Arthritis Research and Therapy, 2011, 13, 246.	1.6	70
67	Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Annals of the Rheumatic Diseases, 2015, 74, 1030-1036.	0.5	70
68	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis and Rheumatology, 2018, 70, 462-467.	2.9	68
69	Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nature Reviews Rheumatology, 2012, 8, 173-181.	3.5	66
70	Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dualâ€Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. Arthritis and Rheumatology, 2019, 71, 1739-1746.	2.9	64
71	Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans. PLoS ONE, 2015, 10, e0119752.	1.1	64
72	Computed tomography measurement of tophus volume: Comparison with physical measurement. Arthritis and Rheumatism, 2007, 57, 461-465.	6.7	63

#	Article	IF	Citations
73	Association of variation in Fc receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples. Annals of the Rheumatic Diseases, 2010, 69, 1711-1716.	0.5	63
74	ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 129-142.	0.4	63
75	Population-specific influence of <i>SLC2A9 </i> genotype on the acute hyperuricaemic response to a fructose load. Annals of the Rheumatic Diseases, 2013, 72, 1868-1873.	0.5	61
76	Discordant association of the CREBRF rs373863828 A allele with increased BMI and protection from type 2 diabetes in MÄori and Pacific (Polynesian) people living in Aotearoa/New Zealand. Diabetologia, 2018, 61, 1603-1613.	2.9	61
77	Assessment of cartilage loss at the wrist in rheumatoid arthritis using a new MRI scoring system. Annals of the Rheumatic Diseases, 2010, 69, 1971-1975.	0.5	58
78	Myeloidâ€Related Proteins 8 and 14 Contribute to Monosodium Urate Monohydrate Crystal–Induced Inflammation in Gout. Arthritis and Rheumatology, 2014, 66, 1327-1339.	2.9	58
79	The anatomical pathology of gout: a systematic literature review. BMC Musculoskeletal Disorders, 2019, 20, 140.	0.8	58
80	Assessment of Tophus Size. Journal of Clinical Rheumatology, 2012, 18, 23-27.	0.5	54
81	Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population. Journal of Rheumatology, 2013, 40, 872-876.	1.0	54
82	Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Research and Therapy, 2015, 17, 288.	1.6	54
83	Progress in Measurement Instruments for Acute and Chronic Gout Studies. Journal of Rheumatology, 2009, 36, 2346-2355.	1.0	53
84	Bone erosions in patients with chronic gouty arthropathy are associated with tophi but not bone oedema or synovitis: new insights from a 3 T MRI study. Rheumatology, 2014, 53, 95-103.	0.9	53
85	Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Annals of the Rheumatic Diseases, 2017, 76, 2065-2070.	0.5	53
86	Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukinâ€8 (CXCL8), Myeloidâ€Related Protein 8/Myeloidâ€Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease. Arthritis and Rheumatology, 2015, 67, 3303-3313.	2.9	51
87	Development of a computed tomography method of scoring bone erosion in patients with gout: validation and clinical implications. Rheumatology, 2011, 50, 410-416.	0.9	50
88	Mendelian Randomization Analysis to Examine for a Causal Effect of Urate on Bone Mineral Density. Journal of Bone and Mineral Research, 2015, 30, 985-991.	3.1	50
89	The incidence and risk factors for falls in adults with rheumatoid arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2015, 44, 389-398.	1.6	50
90	Dual-Energy Computed Tomography for Gout Diagnosis and Management. Current Rheumatology Reports, 2013, 15, 301.	2.1	49

#	Article	IF	Citations
91	Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout. Arthritis and Rheumatology, 2021, 73, 1738-1748.	2.9	49
92	MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. Arthritis Research and Therapy, 2009, 11, R2.	1.6	48
93	Functional and biomechanical characteristics of foot disease in chronic gout: A case-control study. Clinical Biomechanics, 2011, 26, 90-94.	0.5	48
94	Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals. Annals of the Rheumatic Diseases, 2015, 74, 786-790.	0.5	48
95	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 2016, 68, 667-672.	1.5	48
96	Medical specialists' attitudes to prescribing biosimilars. Pharmacoepidemiology and Drug Safety, 2017, 26, 570-577.	0.9	48
97	Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Seminars in Arthritis and Rheumatism, 2017, 46, 457-464.	1.6	48
98	Blocking fatty acid–fueled mROS production within macrophages alleviates acute gouty inflammation. Journal of Clinical Investigation, 2018, 128, 1752-1771.	3.9	48
99	Hyperuricaemia and gout: state of the art and future perspectives. Annals of the Rheumatic Diseases, 2010, 69, 1738-1743.	0.5	47
100	Overexpression of miR-595 and miR-1246 in the Sera of Patients with Active Forms of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 520-530.	0.9	47
101	Gait characteristics associated with the foot and ankle in inflammatory arthritis: a systematic review and meta-analysis. BMC Musculoskeletal Disorders, 2015, 16, 134.	0.8	47
102	Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 2016, 81, 277-289.	1.1	46
103	Populationâ€Specific Resequencing Associates the ATPâ€Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand MÄori and Pacific Men. Arthritis and Rheumatology, 2017, 69, 1461-1469.	2.9	46
104	†Choosing shoes†: a preliminary study into the challenges facing clinicians in assessing footwear for rheumatoid patients. Journal of Foot and Ankle Research, 2010, 3, 24.	0.7	45
105	Serum Urate as a Soluble Biomarker in Chronic Goutâ€"Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers. Seminars in Arthritis and Rheumatism, 2011, 40, 483-500.	1.6	45
106	Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study. Arthritis Care and Research, 2012, 64, 384-388.	1.5	45
107	Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. Annals of the Rheumatic Diseases, 2018, 77, 364-370.	0.5	45
108	Clinical audit of foot problems in patients with rheumatoid arthritis treated at Counties Manukau District Health Board, Auckland, New Zealand. Journal of Foot and Ankle Research, 2009, 2, 16.	0.7	44

#	Article	IF	Citations
109	Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography. Arthritis Research and Therapy, 2012, 14, R165.	1.6	44
110	The genetics of gout: towards personalised medicine?. BMC Medicine, 2017, 15, 108.	2.3	44
111	Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank. Arthritis Research and Therapy, 2017, 19, 181.	1.6	44
112	Effects of Message Framing on Patients' Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch. Arthritis Care and Research, 2020, 72, 1323-1330.	1.5	44
113	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Annals of the Rheumatic Diseases, 2020, 79, 536-544.	0.5	44
114	Impaired response or insufficient dosage?â€"Examining the potential causes of "inadequate response―to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism, 2014, 44, 170-174.	1.6	43
115	Use of imaging to evaluate gout and other crystal deposition disorders. Current Opinion in Rheumatology, 2009, 21, 124-131.	2.0	42
116	Exploratory Study of Radiographic Change in Patients With Tophaceous Gout Treated With Intensive Urate‣owering Therapy. Arthritis Care and Research, 2014, 66, 82-85.	1.5	42
117	Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training. Clinical Rheumatology, 2017, 36, 641-647.	1.0	41
118	Magnetic Resonance Imaging Bone Edema Is Not a Major Feature of Gout Unless There Is Concomitant Osteomyelitis: 10-year Findings from a High-prevalence Population. Journal of Rheumatology, 2011, 38, 2475-2481.	1.0	40
119	Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout. Annals of the Rheumatic Diseases, 2014, 73, 1737-1741.	0.5	40
120	Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskeletal Disorders, 2013, 14, 363.	0.8	39
121	New insights into an old disease: advanced imaging in the diagnosis and management of gout. Postgraduate Medical Journal, 2013, 89, 87-93.	0.9	39
122	The experience and impact of gout in MÄori and Pacific people: a prospective observational study. Clinical Rheumatology, 2013, 32, 247-251.	1.0	39
123	The Effects of Monosodium Urate Monohydrate Crystals on Chondrocyte Viability and Function: Implications for Development of Cartilage Damage in Gout. Journal of Rheumatology, 2013, 40, 2067-2074.	1.0	39
124	Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. Journal of Rheumatology, 2015, 42, 2460-2464.	1.0	39
125	The effect of mindfulness-based stress reduction on disease activity in people with rheumatoid arthritis: a randomised controlled trial. Annals of the Rheumatic Diseases, 2015, 74, 472-474.	0.5	39
126	Reliability of the TekScan MatScan $\hat{A}^{@}$ system for the measurement of postural stability in older people with rheumatoid arthritis. Journal of Foot and Ankle Research, 2012, 5, 21.	0.7	38

#	Article	IF	Citations
127	Ultrasound Features of the First Metatarsophalangeal Joint in Gout and Asymptomatic Hyperuricemia: Comparison With Normouricemic Individuals. Arthritis Care and Research, 2017, 69, 875-883.	1.5	38
128	Measuring bone erosion and edema in rheumatoid arthritis: A comparison of manual segmentation and RAMRIS methods. Journal of Magnetic Resonance Imaging, 2011, 33, 364-371.	1.9	37
129	Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. Annals of the Rheumatic Diseases, 2011, 70, 1091-1094.	0.5	37
130	New classification criteria for gout: a framework for progress. Rheumatology, 2013, 52, 1748-1753.	0.9	37
131	Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study. Arthritis Research and Therapy, 2013, 15, R160.	1.6	37
132	The first metatarsophalangeal joint in gout: a systematic review and meta-analysis. BMC Musculoskeletal Disorders, 2016, 17, 69.	0.8	37
133	Development of a Dualâ€Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout. Arthritis Care and Research, 2016, 68, 769-775.	1.5	37
134	"What say ye gout experts?―a content analysis of questions about gout posted on the social news website Reddit. BMC Musculoskeletal Disorders, 2017, 18, 488.	0.8	37
135	Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. ACR Open Rheumatology, 2021, 3, 333-340.	0.9	37
136	Association Between Gut Microbiota and Elevated Serum Urate in Two Independent Cohorts. Arthritis and Rheumatology, 2022, 74, 682-691.	2.9	37
137	The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity. Arthritis Research and Therapy, 2011, 13, R85.	1.6	36
138	Performance of classification criteria for gout in early and established disease. Annals of the Rheumatic Diseases, 2016, 75, 178-182.	0.5	36
139	Gout – what are the treatment options?. Expert Opinion on Pharmacotherapy, 2009, 10, 1319-1328.	0.9	35
140	The Genetic Basis of Gout. Rheumatic Disease Clinics of North America, 2014, 40, 279-290.	0.8	35
141	Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study. Rheumatology, 2017, 56, 129-133.	0.9	35
142	Factors Associated With Recurrent Hospital Admissions for Gout. Journal of Clinical Rheumatology, 2009, 15, 271-274.	0.5	34
143	Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption. Arthritis Research and Therapy, 2013, 15, R177.	1.6	34
144	Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care and Research, 2016, 68, 1894-1898.	1.5	34

#	Article	IF	CITATIONS
145	"You Don't Have to Be a Drinker to Get Gout, But It Helps― A Content Analysis of the Depiction of Gout in Popular Newspapers. Arthritis Care and Research, 2016, 68, 1721-1725.	1.5	34
146	Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology, 2018, 57, 656-660.	0.9	34
147	Footwear characteristics and factors influencing footwear choice in patients with gout. Arthritis Care and Research, 2011, 63, 1599-1604.	1.5	33
148	The effects of commercially available footwear on foot pain and disability in people with gout: a pilot study. BMC Musculoskeletal Disorders, 2013, 14, 278.	0.8	33
149	Urate crystal deposition and bone erosion in gout: â€inside-out' or â€outside-in'? A dual-energy compute tomography study. Arthritis Research and Therapy, 2016, 18, 208.	d.6	33
150	Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskeletal Disorders, 2012, 13, 174.	0.8	32
151	Dual-Energy CT of Urate Deposits in Costal Cartilage and Intervertebral Disks of Patients With Tophaceous Gout and Age-Matched Controls. American Journal of Roentgenology, 2016, 206, 1063-1067.	1.0	32
152	Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. Seminars in Arthritis and Rheumatism, 2018, 48, 293-301.	1.6	32
153	Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state. Arthritis Research and Therapy, 2018, 20, 208.	1.6	32
154	Pathophysiology of Gout. Seminars in Nephrology, 2020, 40, 550-563.	0.6	32
155	Effects of Dairy Intake on Hyperuricemia and Gout. Current Rheumatology Reports, 2011, 13, 132-137.	2.1	31
156	Imaging of gout – An overview. Best Practice and Research in Clinical Rheumatology, 2012, 26, 823-838.	1.4	31
157	The Intentional Non-Adherence Scale (INAS): Initial development and validation. Journal of Psychosomatic Research, 2018, 115, 110-116.	1.2	31
158	The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. PLoS ONE, 2016, 11, e0147939.	1.1	31
159	Imaging in gout. Current Opinion in Rheumatology, 2012, 24, 132-138.	2.0	30
160	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. Annals of the Rheumatic Diseases, 2016, 75, 1363-1366.	0.5	30
161	Mitochondrial genetic variation and gout in MÄori and Pacific people living in Aotearoa New Zealand. Annals of the Rheumatic Diseases, 2018, 77, 571-578.	0.5	30
162	Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. Rheumatology, 2020, 59, 2544-2549.	0.9	30

#	Article	IF	Citations
163	DECT urate deposits: now you see them, now you don't. Annals of the Rheumatic Diseases, 2013, 72, 458-459.	0.5	29
164	Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout. Arthritis Research and Therapy, 2017, 19, 161.	1.6	29
165	Human Cartilage Homogenates Influence the Crystallization of Monosodium Urate and Inflammatory Response to Monosodium Urate Crystals: A Potential Link Between Osteoarthritis and Gout. Arthritis and Rheumatology, 2019, 71, 2090-2099.	2.9	29
166	Identification of dairy fractions with anti-inflammatory properties in models of acute gout. Annals of the Rheumatic Diseases, 2010, 69, 766-769.	0.5	28
167	Nail Disease in Psoriatic Arthritis: Distal Phalangeal Bone Edema Detected by Magnetic Resonance Imaging Predicts Development of Onycholysis and Hyperkeratosis. Journal of Rheumatology, 2012, 39, 841-843.	1.0	28
168	Outcome Measures in Acute Gout: A Systematic Literature Review. Journal of Rheumatology, 2014, 41, 558-568.	1.0	28
169	Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study. Journal of Rheumatology, 2017, 44, 368-373.	1.0	28
170	The effect of different styles of medical illustration on information comprehension, the perception of educational material and illness beliefs. Patient Education and Counseling, 2020, 103, 556-562.	1.0	28
171	The experience of a gout flare: a meta-synthesis of qualitative studies. Seminars in Arthritis and Rheumatism, 2020, 50, 805-811.	1.6	28
172	Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout. Arthritis Research and Therapy, 2020, 22, 45.	1.6	28
173	Outcome evaluations in gout. Journal of Rheumatology, 2007, 34, 1381-5.	1.0	28
174	The sixâ€minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology, 2012, 17, 647-652.	1.3	27
175	Influence of the ABCG2 gout risk 141ÂK allele on urate metabolism during a fructose challenge. Arthritis Research and Therapy, 2014, 16, R34.	1.6	27
176	Imaging in the Crystal Arthropathies. Rheumatic Disease Clinics of North America, 2014, 40, 231-249.	0.8	27
177	Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. BMC Musculoskeletal Disorders, 2015, 16, 196.	0.8	27
178	An association of smoking with serum urate and gout: A health paradox. Seminars in Arthritis and Rheumatism, 2018, 47, 825-842.	1.6	27
179	Inflammation and tissue damage in crystal deposition diseases. Current Opinion in Rheumatology, 2005, 17, 314-318.	2.0	26
180	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 569-573.	1.0	26

#	Article	IF	CITATIONS
181	Advances in pharmacotherapy for the treatment of gout. Expert Opinion on Pharmacotherapy, 2015, 16, 533-546.	0.9	26
182	Review: Gout: A Roadmap to Approaches for Improving Global Outcomes. Arthritis and Rheumatology, 2017, 69, 22-34.	2.9	26
183	Association Between User Engagement of a Mobile Health App for Gout and Improvements in Self-Care Behaviors: Randomized Controlled Trial. JMIR MHealth and UHealth, 2019, 7, e15021.	1.8	26
184	Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology, 2012, 51, 1820-1824.	0.9	25
185	A Delphi Exercise to Identify Characteristic Features of Gout — Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria. Journal of Rheumatology, 2013, 40, 498-505.	1.0	25
186	Toward Development of a Tophus Impact Questionnaire. Journal of Clinical Rheumatology, 2014, 20, 251-255.	0.5	25
187	Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2014, 73, 1044-1051.	0.5	25
188	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. Journal of Rheumatology, 2016, 43, 150-153.	1.0	25
189	Population-specific association between ABCG2 variants and tophaceous disease in people with gout. Arthritis Research and Therapy, 2017, 19, 43.	1.6	25
190	MRI in psoriatic arthritis: Insights into pathogenesis and treatment response. Current Rheumatology Reports, 2008, 10, 303-310.	2.1	24
191	Obstacles to action in arthritis: a community caseâ€control study. International Journal of Rheumatic Diseases, 2009, 12, 107-117.	0.9	24
192	Quantifying synovitis in rheumatoid arthritis using computerâ€assisted manual segmentation with 3 tesla MRI scanning. Journal of Magnetic Resonance Imaging, 2011, 33, 1106-1113.	1.9	24
193	Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. Arthritis Research and Therapy, 2015, 17, 263.	1.6	24
194	The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. Arthritis Research and Therapy, 2017, 19, 283.	1.6	24
195	Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials. Journal of Rheumatology, 2011, 38, 1467-1470.	1.0	23
196	The effects of experimental knee pain on lower limb corticospinal and motor cortex excitability. Arthritis Research and Therapy, 2015, 17, 204.	1.6	23
197	Patterns of foot complaints in systemic lupus erythematosus: a cross sectional survey. Journal of Foot and Ankle Research, 2016, 9, 10.	0.7	23
198	Footwear interventions for foot pain, function, impairment and disability for people with foot and ankle arthritis: A literature review. Seminars in Arthritis and Rheumatism, 2018, 47, 814-824.	1.6	23

#	Article	IF	Citations
199	The relationship between ferritin and urate levels and risk of gout. Arthritis Research and Therapy, 2018, 20, 179.	1.6	23
200	Gout, flares, and allopurinol use: a population-based study. Arthritis Research and Therapy, 2019, 21, 132.	1.6	23
201	Prevention and treatment of gout. Nature Reviews Rheumatology, 2019, 15, 68-70.	3.5	23
202	Representation of Women as Authors of Rheumatology Research Articles. Arthritis and Rheumatology, 2021, 73, 162-167.	2.9	23
203	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. Arthritis Care and Research, 2022, 74, 1649-1658.	1.5	23
204	Gender and Ethnic Inequities in Gout Burden and Management. Rheumatic Disease Clinics of North America, 2020, 46, 693-703.	0.8	23
205	The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout. Arthritis Research and Therapy, 2014, 16, 495.	1.6	22
206	Consensus-based semi-quantitative ultrasound scoring system for gout lesions: Results of an OMERACT Delphi process and web-reliability exercise. Seminars in Arthritis and Rheumatism, 2021, 51, 644-649.	1.6	22
207	Interventions to improve uptake of urate-lowering therapy in patients with gout: a systematic review. BJGP Open, 2020, 4, bjgpopen20X101051.	0.9	22
208	Imaging Features of Calcium Pyrophosphate Deposition Disease: Consensus Definitions From an International Multidisciplinary Working Group. Arthritis Care and Research, 2023, 75, 825-834.	1.5	22
209	Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities. Journal of Rheumatology, 2011, 38, 1458-1461.	1.0	21
210	Do Patient Preferences for Core Outcome Domains for Chronic Gout Studies Support the Validity of Composite Response Criteria?. Arthritis Care and Research, 2013, 65, 1259-1264.	1.5	21
211	Combination urate-lowering therapy in the treatment of gout: What is the evidence?. Seminars in Arthritis and Rheumatism, 2019, 48, 658-668.	1.6	21
212	Reply. Arthritis Care and Research, 2020, 72, 1507-1508.	1.5	21
213	Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Rheumatology International, 2021, 41, 163-171.	1.5	21
214	Lymphocytes in pleural disease. Current Opinion in Pulmonary Medicine, 2005, 11, 334-339.	1.2	20
215	The Patient's Experience of Gout: New Insights to Optimize Management. Current Rheumatology Reports, 2012, 14, 173-178.	2.1	20
216	Febuxostat for the treatment of hyperuricaemia in gout. Expert Opinion on Pharmacotherapy, 2018, 19, 1289-1299.	0.9	20

#	Article	IF	Citations
217	Screening for hyperuricaemia and gout: a perspective and research agenda. Nature Reviews Rheumatology, 2014, 10, 752-756.	3.5	19
218	The effects of sandals on postural stability in patients with rheumatoid arthritis: An exploratory study. Clinical Biomechanics, 2014, 29, 350-353.	0.5	19
219	Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20). Annals of the Rheumatic Diseases, 2015, 74, 2144-2150.	0.5	19
220	We read spam a lot: prospective cohort study of unsolicited and unwanted academic invitations. BMJ, The, 2016, 355, i5383.	3.0	19
221	Imaging as a potential outcome measure in gout studies: A systematic literature review. Seminars in Arthritis and Rheumatism, 2016, 45, 570-579.	1.6	19
222	Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study. BMJ Open, 2017, 7, e017019.	0.8	19
223	Analysis of data collected from right and left limbs: Accounting for dependence and improving statistical efficiency in musculoskeletal research. Gait and Posture, 2018, 59, 182-187.	0.6	19
224	Overlay repair with a synthetic collagen scaffold improves the quality of healing in a rat rotator cuff repair model. Journal of Shoulder and Elbow Surgery, 2019, 28, 949-958.	1.2	19
225	Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. Arthritis Research and Therapy, 2019, 21, 13.	1.6	19
226	The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect. Arthritis Research and Therapy, 2021, 23, 75.	1.6	19
227	An illness by any other name: The effect of renaming gout on illness and treatment perceptions Health Psychology, 2018, 37, 37-41.	1.3	19
228	Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. Lancet Rheumatology, The, 2022, 4, e274-e281.	2.2	19
229	The effects of joint aspiration and intra-articular corticosteroid injection on flexion reflex excitability, quadriceps strength and pain in individuals with knee synovitis: a prospective observational study. Arthritis Research and Therapy, 2015, 17, 191.	1.6	18
230	Severe gout: Strategies and innovations for effective management. Joint Bone Spine, 2017, 84, 541-546.	0.8	18
231	Region-specific foot pain and plantar pressure in people with rheumatoid arthritis: A cross-sectional study. Clinical Biomechanics, 2018, 55, 14-17.	0.5	18
232	Gout. Rheumatic Disease Clinics of North America, 2019, 45, 583-591.	0.8	18
233	Development of a prediction model for inpatient gout flares in people with comorbid gout. Annals of the Rheumatic Diseases, 2020, 79, 418-423.	0.5	18
234	Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatology, The, 2022, 4, e53-e60.	2.2	18

#	Article	IF	Citations
235	The natural killer cell: a further innate mediator of gouty inflammation?. Immunology and Cell Biology, 2010, 88, 24-31.	1.0	17
236	Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?. Journal of Rheumatology, 2011, 38, 1462-1466.	1.0	17
237	The effect of good and poor walking shoe characteristics on plantar pressure and gait in people with gout. Clinical Biomechanics, 2014, 29, 1158-1163.	0.5	17
238	Structural Joint Damage in Gout. Rheumatic Disease Clinics of North America, 2014, 40, 291-309.	0.8	17
239	Foot-related pain and disability and spatiotemporal parameters of gait during self-selected and fast walking speeds in people with gout: A two-arm cross sectional study. Gait and Posture, 2016, 44, 18-22.	0.6	17
240	Ultrasound Characteristics of the Achilles Tendon in Tophaceous Gout: A Comparison with Age- and Sex-matched Controls. Journal of Rheumatology, 2017, 44, 1487-1492.	1.0	17
241	Prevalence and discrimination of OMERACT-defined elementary ultrasound lesions of gout in people with asymptomatic hyperuricaemia: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2019, 49, 62-73.	1.6	17
242	Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Research and Therapy, 2019, 21, 8.	1.6	17
243	Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. Rheumatology, 2022, 61, SI81-SI85.	0.9	17
244	Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease. Annals of Internal Medicine, 2022, 175, 461-470.	2.0	17
245	Application of the OMERACT Filter to Measures of Core Outcome Domains in Recent Clinical Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 574-580.	1.0	16
246	Characteristics of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: a crossâ€sectional observational study. Journal of Foot and Ankle Research, 2015, 8, 41.	0.7	16
247	Association of SLC2A9 genotype with phenotypic variability of serum urate in pre-menopausal women. Frontiers in Genetics, 2015, 6, 313.	1.1	16
248	Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. Rheumatology, 2016, 55, 1421-1430.	0.9	16
249	Are Foot and Ankle Characteristics Associated With Falls in People With Rheumatoid Arthritis? A Prospective Study. Arthritis Care and Research, 2017, 69, 1150-1155.	1.5	16
250	Illness Perceptions and Mortality in Patients With Gout: A Prospective Observational Study. Arthritis Care and Research, 2017, 69, 1444-1448.	1.5	16
251	Advanced imaging assessment of gout: comparison of dual-energy CT and MRI with anatomical pathology. Annals of the Rheumatic Diseases, 2018, 77, 629-630.	0.5	16
252	Mediation analysis to understand genetic relationships between habitual coffee intake and gout. Arthritis Research and Therapy, 2018, 20, 135.	1.6	16

#	Article	IF	CITATIONS
253	Altered N-methyl D-aspartate receptor subunit expression causes changes to the circadian clock and cell phenotype in osteoarthritic chondrocytes. Osteoarthritis and Cartilage, 2018, 26, 1518-1530.	0.6	16
254	Altered expression of the core circadian clock component PERIOD2 contributes to osteoarthritis-like changes in chondrocyte activity. Chronobiology International, 2019, 36, 319-331.	0.9	16
255	How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials. Seminars in Arthritis and Rheumatism, 2020, 50, 303-313.	1.6	16
256	The PTPN22 Locus and Rheumatoid Arthritis: No Evidence for an Effect on Risk Independent of Arg620Trp. PLoS ONE, 2010, 5, e13544.	1.1	15
257	A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management. Journal of Primary Health Care, 2016, 8, 149.	0.2	15
258	Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations. Journal of Foot and Ankle Research, 2016, 9, 15.	0.7	15
259	Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. Journal of Rheumatology, 2018, 45, 419-424.	1.0	15
260	Genetic advances in gout: potential applications in clinical practice. Current Opinion in Rheumatology, 2019, 31, 144-151.	2.0	15
261	Experience of finding footwear and factors contributing to footwear choice in people with gout: a mixed methods study using a webâ€based survey. Journal of Foot and Ankle Research, 2019, 12, 3.	0.7	15
262	The MÄøri and Pacific specific CREBRF variant and adult height. International Journal of Obesity, 2020, 44, 748-752.	1.6	15
263	Patients with gout: an under-recognised group at high risk of COVID-19. Lancet Rheumatology, The, 2021, 3, e317-e318.	2.2	15
264	Intensive Serum Urate Lowering With Oral Urateâ€Lowering Therapy for Erosive Gout: A Randomized Doubleâ€Blind Controlled Trial. Arthritis and Rheumatology, 2022, 74, 1059-1069.	2.9	15
265	Clinicallyâ€evident tophi are associated with reduced muscle force in the foot and ankle in people with gout: a crossâ€sectional study. Journal of Foot and Ankle Research, 2017, 10, 25.	0.7	14
266	The risk of clinically diagnosed gout by serum urate levels: results from 30Âyears follow-up of the Malmö Preventive Project cohort in southern Sweden. Arthritis Research and Therapy, 2018, 20, 190.	1.6	14
267	Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy. Rheumatology, 2022, 61, 4898-4904.	0.9	14
268	Superiority of <scp>Lowâ€Dose</scp> Benzbromarone to <scp>Lowâ€Dose</scp> Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion. Arthritis and Rheumatology, 2022, 74, 2015-2023.	2.9	14
269	Replication of association of the interleukin 23 receptor rs1343151 variant with rheumatoid arthritis in Caucasian sample sets. Annals of the Rheumatic Diseases, 2012, 71, 155-157.	0.5	13
270	Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study. Annals of the Rheumatic Diseases, 2013, 72, 1583-1584.	0.5	13

#	Article	IF	CITATIONS
271	Factors associated with change in radiographic damage scores in gout: a prospective observational study. Annals of the Rheumatic Diseases, 2016, 75, 2075-2079.	0.5	13
272	Are ultrasound features at the first metatarsophalangeal joint associated with clinicallyâ€assessed pain and function? A study of people with gout, asymptomatic hyperuricaemia and normouricaemia. Journal of Foot and Ankle Research, 2017, 10, 22.	0.7	13
273	The challenges of gout flare reporting: mapping flares during a randomized controlled trial. BMC Rheumatology, 2019, 3, 27.	0.6	13
274	Concurrent validity of provisional remission criteria for gout: a dual-energy CT study. Arthritis Research and Therapy, 2019, 21, 150.	1.6	13
275	Effects of a footwear intervention on foot pain and disability in people with gout: a randomised controlled trial. Arthritis Research and Therapy, 2019, 21, 104.	1.6	13
276	Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Phenotype Markers in Primary Human Chondrocytes by a Calcium/Calmodulin Kinase 2-Dependent Mechanism. Calcified Tissue International, 2019, 104, 331-343.	1.5	13
277	The effect of diet-induced obesity on the inflammatory phenotype of non-adipose-resident macrophages in an in vivo model of gout. Rheumatology, 2014, 53, 1901-1905.	0.9	12
278	Path Analysis Identifies Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout. Journal of Rheumatology, 2016, 43, 445-449.	1.0	12
279	Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis. Rheumatology, 2017, 56, 1335-1341.	0.9	12
280	Lesinurad for the treatment of hyperuricaemia in people with gout. Expert Opinion on Pharmacotherapy, 2017, 18, 1875-1881.	0.9	12
281	The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring. Journal of Rheumatology, 2018, 45, 697-704.	1.0	12
282	Management of complex gout in clinical practice: Update on therapeutic approaches. Best Practice and Research in Clinical Rheumatology, 2018, 32, 813-834.	1.4	12
283	"Come and live with my feet and you'll understand―– a qualitative study exploring the experiences of retail footwear in women with rheumatoid arthritis. Journal of Foot and Ankle Research, 2019, 12, 15.	0.7	12
284	The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors—30 years follow-up of the Malmö Preventive Project. Arthritis Research and Therapy, 2020, 22, 244.	1.6	12
285	Gout Flare Severity From the Patient Perspective: A Qualitative Interview Study. Arthritis Care and Research, 2022, 74, 317-323.	1.5	12
286	Epidemiology of tendon and ligament injuries in Aotearoa/New Zealand between 2010 and 2016. Injury Epidemiology, 2020, 7, 5.	0.8	12
287	Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers. New Zealand Medical Journal, 2014, 127, 37-47.	0.5	12
288	Complementary and Alternative Medicine Use in Patients With Gout. Journal of Clinical Rheumatology, 2014, 20, 16-20.	0.5	11

#	Article	IF	Citations
289	Relationship between tissue stress during gait in healthy volunteers and patterns of urate deposition and bone erosion in gout: a biomechanical computational modelling study. RMD Open, 2015, 1, e000101.	1.8	11
290	Foot and ankle muscle strength in people with gout: A two-arm cross-sectional study. Clinical Biomechanics, 2016, 32, 207-211.	0.5	11
291	The impact of diuretic use and <i>ABCG2</i> genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 2018, 84, 937-943.	1.1	11
292	Imaging tools to measure treatment response in gout. Rheumatology, 2018, 57, i27-i34.	0.9	11
293	Population-specific factors associated with fractional excretion of uric acid. Arthritis Research and Therapy, 2019, 21, 234.	1.6	11
294	Liposome-Mediated Drug Delivery in Larval Zebrafish to Manipulate Macrophage Function. Zebrafish, 2019, 16, 171-181.	0.5	11
295	Internalized and Anticipated Stigmatization in Patients With Gout. ACR Open Rheumatology, 2020, 2, 11-17.	0.9	11
296	Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers. Arthritis Research and Therapy, 2020, 22, 259.	1.6	11
297	Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout. Journal of Rheumatology, 2021, 48, 293-298.	1.0	11
298	Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 946-950.	1.6	11
299	Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. New Zealand Medical Journal, 2018, 131, 8-12.	0.5	11
300	Quantifying Bone Marrow Edema in the Rheumatoid Cervical Spine Using Magnetic Resonance Imaging. Journal of Rheumatology, 2010, 37, 1626-1632.	1.0	10
301	Nurse-Led Cardiovascular Disease Risk Management Intervention for Patients with Gout. European Journal of Cardiovascular Nursing, 2011, 10, 94-100.	0.4	10
302	Progress and controversies in treatment. Nature Reviews Rheumatology, 2011, 7, 77-78.	3.5	10
303	Digital tomosynthesis for bone erosion scoring in gout: comparison with plain radiography and computed tomography. Rheumatology, 2014, 53, 1712-1713.	0.9	10
304	Sugar Sweetened Beverage Consumption among Adults with Gout or Type 2 Diabetes. PLoS ONE, 2015, 10, e0125543.	1.1	10
305	Lack of direct evidence for natural selection at the candidate thrifty gene locus, PPARGC1A. BMC Medical Genetics, 2016, 17, 80.	2.1	10
306	Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout. Rheumatology International, 2016, 36, 255-261.	1.5	10

#	Article	IF	CITATIONS
307	Bovine bone particulates containing bone anabolic factors as a potential xenogenic bone graft substitute. Journal of Orthopaedic Surgery and Research, 2019, 14, 60.	0.9	10
308	Do Serum Urate–Associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank. Arthritis and Rheumatology, 2020, 72, 1184-1191.	2.9	10
309	Raman spectroscopy reveals age- and sex-related differences in cortical bone from people with osteoarthritis. Scientific Reports, 2020, 10, 19443.	1.6	10
310	Outcome domains reported in calcium pyrophosphate deposition studies: A scoping review by the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2020, 50, 719-727.	1.6	10
311	Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Metaâ€Analysis. Arthritis Care and Research, 2021, 73, 755-764.	1.5	10
312	Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial. Arthritis and Rheumatology, 2021, 73, 721-724.	2.9	10
313	Why compare the effectiveness of suboptimal gout management?. Nature Reviews Rheumatology, 2015, 11, 506-507.	3.5	9
314	Renal dosing of allopurinol results in suboptimal gout care. Annals of the Rheumatic Diseases, 2017, 76, e1-e1.	0.5	9
315	Plasma oxypurinol as a measure of adherence in clinical trials. Annals of the Rheumatic Diseases, 2018, 77, 313-314.	0.5	9
316	How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research and Therapy, 2018, 20, 255.	1.6	9
317	Googling Gout: Exploring Perceptions About Gout Through a Linguistic Analysis of Online Search Activities. Arthritis Care and Research, 2019, 71, 419-426.	1.5	9
318	Relationship between Gout and Diabetes Mellitus after Acute Pancreatitis: A Nationwide Cohort Study. Journal of Rheumatology, 2020, 47, 917-923.	1.0	9
319	Objectively Assessed Foot and Ankle Characteristics in Patients With Systemic Lupus Erythematosus: A Comparison With Age―and Sexâ€Matched Controls. Arthritis Care and Research, 2020, 72, 122-130.	1.5	9
320	Inequities in people with gout: a focus on MÄøri (Indigenous People) of Aotearoa New Zealand. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110280.	1.2	9
321	Limitations of dual-energy CT in the detection of monosodium urate deposition in dense liquid tophi and calcified tophi. Skeletal Radiology, 2021, 50, 1667-1675.	1.2	9
322	Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2021, 51, 677-684.	1.6	9
323	Association of acidic urine pH with impaired renal function in primary gout patients: a Chinese population-based cross-sectional study. Arthritis Research and Therapy, 2022, 24, 32.	1.6	9
324	Gastrointestinal disease and psoriatic arthritis. Journal of Rheumatology, 2004, 31, 1469-70.	1.0	9

#	Article	IF	CITATIONS
325	Gout and the COVID-19 pandemic. Current Opinion in Rheumatology, 2022, 34, 111-117.	2.0	9
326	Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatology, 2008, 3, 421-427.	0.2	8
327	Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders. Medical Hypotheses, 2009, 73, 651-654.	0.8	8
328	Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone. Joint Bone Spine, 2014, 81, 160-163.	0.8	8
329	A comparative MRI study of cartilage damage in gout versus rheumatoid arthritis. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 431-435.	0.9	8
330	The assessment of lesions of the Achilles tendon by ultrasound imaging in inflammatory arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2015, 45, 103-114.	1.6	8
331	Is the Double Contour Sign Specific for Gout? Or Only for Crystal Arthritis?. Journal of Rheumatology, 2015, 42, 353-354.	1.0	8
332	Ankle joint function during walking in tophaceous gout: A biomechanical gait analysis study. Gait and Posture, 2018, 63, 150-153.	0.6	8
333	Foot and ankle characteristics in systemic lupus erythematosus: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2019, 48, 847-859.	1.6	8
334	The footwear experiences of people with gout: a qualitative study. Journal of Foot and Ankle Research, 2019, 12, 38.	0.7	8
335	The circadian clock: a central mediator of cartilage maintenance and osteoarthritis development?. Rheumatology, 2021, 60, 3048-3057.	0.9	8
336	Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD): A content analysis based on semi-structured qualitative interviews from the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 650-654.	1.6	8
337	Aotearoa New Zealand MÄori and Pacific Population-amplified Gout Risk Variants: <i>CLNK</i> Is a Separate Risk Gene at the <i>SLC2A9</i> Locus. Journal of Rheumatology, 2021, 48, 1736-1744.	1.0	8
338	Assessing the Relationship Between Serum Urate and Urolithiasis Using Mendelian Randomization: An Analysis of the UK Biobank. American Journal of Kidney Diseases, 2021, 78, 210-218.	2.1	8
339	Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination. Annals of the Rheumatic Diseases, 2022, 81, 1189-1193.	0.5	8
340	Cytotoxicity of tranexamic acid to tendon and bone in vitro: Is there a safe dosage?. Journal of Orthopaedic Surgery and Research, 2022, 17, 273.	0.9	8
341	Population-specific effects of <i> SLC17A1 &lt; /i &gt; genotype on serum urate concentrations and renal excretion of uric acid during a fructose load. Annals of the Rheumatic Diseases, 2014, 73, 313-314.</i>	0.5	7
342	Outcome Measures for Gout Clinical Trials: a Summary of Progress. Current Treatment Options in Rheumatology, 2015, 1, 156-166.	0.6	7

#	Article	IF	Citations
343	Predictors of activity limitation in people with gout: a prospective study. Clinical Rheumatology, 2018, 37, 2213-2219.	1.0	7
344	ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol. Drug Metabolism and Pharmacokinetics, 2018, 33, 241-242.	1.1	7
345	Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout – A cluster pattern analysis of dual-energy CT. Seminars in Arthritis and Rheumatism, 2020, 50, 54-58.	1.6	7
346	The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychology Review, 2023, 17, 148-168.	4.4	7
347	Relationship Between Changes in Serum Urate and Bone Mineral Density During Treatment with Thiazide Diuretics: Secondary Analysis from a Randomized Controlled Trial. Calcified Tissue International, 2016, 98, 474-478.	1.5	6
348	Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 2018, 57, 2183-2189.	0.9	6
349	No association between <i>ATP-binding cassette transporter G2</i> rs2231142 (Q141K) and urate-lowering response to febuxostat. Rheumatology, 2019, 58, 547-548.	0.9	6
350	Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urateâ€Lowering Responseâ€"In Search of a Minimum Effective Oxypurinol Concentration. Clinical and Translational Science, 2020, 13, 110-115.	1.5	6
351	Costâ€Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol. Arthritis Care and Research, 2021, 73, 1537-1543.	1.5	6
352	Not Every Picture Tells a Story: A Content Analysis of Visual Images in Patient Educational Resources About Gout. Journal of Rheumatology, 2020, 47, 1815-1821.	1.0	6
353	Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. Journal of Human Genetics, 2021, 66, 161-169.	1.1	6
354	Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016–2020. Annals of the Rheumatic Diseases, 2021, 80, 1095-1096.	0.5	6
355	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout. RMD Open, 2021, 7, e001623.	1.8	6
356	A bio-what? Medical companions' perceptions towards biosimilars and information needs in rheumatology. Rheumatology International, 2022, 42, 1993-2002.	1.5	6
357	Diagnostic value of different imaging features for patients with suspected gout: A network meta-analysis. Seminars in Arthritis and Rheumatism, 2021, 51, 1251-1257.	1.6	6
358	Commentary: controversies in NICE guidance on osteoarthritis. BMJ: British Medical Journal, 2008, 336, 504.1-504.	2.4	5
359	Clinical and genetic features of diuretic-associated gout: a case-control study. Rheumatology, 2016, 55, 1172-1176.	0.9	5
360	Gout on CT of the feet: A symmetric arthropathy. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 54-58.	0.9	5

#	Article	IF	Citations
361	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. BMJ Open, 2016, 6, e012026.	0.8	5
362	What Is the Evidence for Treat-to-Target Serum Urate in Gout?. Current Rheumatology Reports, 2018, 20, 11.	2.1	5
363	The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. Seminars in Arthritis and Rheumatism, 2018, 48, 456-461.	1.6	5
364	Patient education and engagement in treat-to-target gout care. Lancet, The, 2018, 392, 1379-1381.	6.3	5
365	Re: "Widespread prevalence of a CREBRF variant among MÄori and Pacific children is associated with weight and height in early childhood― International Journal of Obesity, 2018, 42, 1389-1391.	1.6	5
366	Keeping Up with the Applications: Lessons Learned Evaluating Gout Apps. Telemedicine Journal and E-Health, 2019, 25, 272-273.	1.6	5
367	Mindfulness-Based Stress Reduction with Individuals Who Have Rheumatoid Arthritis: Evaluating Depression and Anxiety as Mediators of Change in Disease Activity. Mindfulness, 2019, 10, 1328-1338.	1.6	5
368	Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!. British Journal of Clinical Pharmacology, 2019, 85, 1378-1379.	1.1	5
369	Which factors predict discordance between a patient and physician on a gout flare?. Rheumatology, 2021, 60, 773-779.	0.9	5
370	"An apple pie a day does not keep the doctor away― Fictional depictions of gout in contemporary film andÂtelevision. BMC Rheumatology, 2021, 5, 4.	0.6	5
371	Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 655-660.	1.6	5
372	Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. Arthritis and Rheumatology, 2021, 73, 1758-1764.	2.9	5
373	Is Three a Crowd? The Influence of Companions on a Patient's Decision to Transition to a Biosimilar. Annals of Behavioral Medicine, 2022, 56, 512-522.	1.7	5
374	Mid-pass whole genome sequencing enables biomedical genetic studies of diverse populations. BMC Genomics, 2021, 22, 666.	1.2	5
375	Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol. International Journal for Equity in Health, 2021, 20, 262.	1.5	5
376	No Reduction in Circulating Preosteoclasts 18 Months after Treatment with Zoledronate: Analysis from a Randomized Placebo Controlled Trial. Calcified Tissue International, 2013, 92, 1-5.	1.5	4
377	Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study. Calcified Tissue International, 2018, 102, 73-84.	1.5	4
378	The patient experience of musculoskeletal imaging tests for investigation of inflammatory arthritis: a mixed-methods study. Clinical Rheumatology, 2018, 37, 2261-2268.	1.0	4

#	Article	IF	CITATIONS
379	Characteristics of footwear worn by people with systemic lupus erythematosus: a comparison with age―and sexâ€matched healthy controls: a pilot study. Journal of Foot and Ankle Research, 2018, 11, 38.	0.7	4
380	Does seeing personal medical images change beliefs about illness and treatment in people with gout? A randomised controlled trial. Psychology and Health, 2020, 35, 107-123.	1.2	4
381	Radiographic damage scores predict grip strength in patients with tophaceous gout. Rheumatology, 2020, 59, 1440-1442.	0.9	4
382	What is remission in gout and how should we measure it?. Rheumatology, 2021, 60, 1007-1009.	0.9	4
383	The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation. Rheumatology, 2022, 61, 1658-1662.	0.9	4
384	Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. PeerJ, 2018, 6, e5088.	0.9	4
385	Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dualâ€energy computed tomography and compensated polarizing light microscopy. Arthritis and Rheumatology, 2022, 74, 1295-1296.	2.9	4
386	Gout in Aotearoa New Zealand: are we going to ignore this for another 3 years?. New Zealand Medical Journal, 2016, 129, 10-3.	0.5	4
387	Why Do Patients With Gout Not Take Allopurinol?. Journal of Rheumatology, 2022, 49, 622-626.	1.0	4
388	A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout. Arthritis Research and Therapy, 2022, 24, 67.	1.6	4
389	Risk of gout flares after COVID-19 vaccination: A case-crossover study. Seminars in Arthritis and Rheumatism, 2022, 56, 152059.	1.6	4
390	Clinical images: Divergent patterns of joint remodeling following effective urateâ€lowering therapy in tophaceous gout. Arthritis and Rheumatism, 2011, 63, 266-266.	6.7	3
391	Evaluating Intratester Reliability of Manual Masking of Plantar Pressure Measurements Associated with Chronic Gout. Journal of the American Podiatric Medical Association, 2011, 101, 424-429.	0.2	3
392	Clarification of the Modified Radiographic Damage Scoring Method for Gout. Journal of Rheumatology, 2012, 39, 874.1-874.	1.0	3
393	Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study. RMD Open, 2017, 3, e000424.	1.8	3
394	Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 241.	1.6	3
395	Making the right thing the easy thing to do: strategies to improve outcomes in gout. Lancet Rheumatology, The, 2019, 1, e122-e131.	2.2	3
396	Greater insulin response to acute fructose ingestion among MÄori and Pacific people compared to European people living in Aotearoa New Zealand. Internal Medicine Journal, 2019, 49, 196-202.	0.5	3

#	Article	IF	CITATIONS
397	Strategies to reduce the impact of smoking on rheumatoid arthritis outcomes: Clinical experience of a brief outpatient clinic screening questionnaire. Comment on "The impact of smoking on rheumatoid arthritis outcomes.―By Vittecoq et al. Joint Bone Spine 2018;85:135–138. Joint Bone Spine, 2019, 86, 275.	0.8	3
398	Article placement order in rheumatology journals: a content analysis. BMJ Open, 2020, 10, e034550.	0.8	3
399	Time to recognise gout as a chronic disease. Medical Journal of Australia, 2020, 212, 285.	0.8	3
400	The impact of the illness label â€~gout' on illness and treatment perceptions in MÄori (Indigenous New) Tj ET	Qq0,0 0 rg	gBŢ /Overlock
401	Urate Lowering for Blood Pressure Control in Adults: Another Nail in the Coffin?. Arthritis and Rheumatology, 2021, 73, 1408-1411.	2.9	3
402	Phenotypic and Functional Analysis of Synovial Natural Killer Cells. Methods in Molecular Medicine, 2007, 136, 149-163.	0.8	3
403	The challenge of gout flare measurement. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101716.	1.4	3
404	Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 1378-1385.	1.6	3
405	Where are the women â€~Heroes and Pillars of Rheumatology'?. Annals of the Rheumatic Diseases, 2023, 82, e199-e199.	0.5	3
406	Changes in Physiological Tendon Substrate Stiffness Have Moderate Effects on Tendon-Derived Cell Growth and Immune Cell Activation. Frontiers in Bioengineering and Biotechnology, 2022, 10, 800748.	2.0	3
407	Diversity of invited speakers at endocrinology conferences. Clinical Endocrinology, 2022, 96, 907-913.	1.2	3
408	A Polynesian-specific copy number variant encompassing the MICA gene associates with gout. Human Molecular Genetics, 2022, 31, 3757-3768.	1.4	3
409	Are we asking the right questions about urateâ€lowering therapy? Comment on the 2021 Asiaâ€Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. International Journal of Rheumatic Diseases, 2022, 25, 714-715.	0.9	3
410	Basic calcium phosphate crystals induce the expression of extracellular matrix remodelling enzymes in tenocytes. Rheumatology, $0$ , , .	0.9	3
411	A new 'package of care' strategy for effective gout management. Nature Reviews Rheumatology, 2012, 8, 507-508.	3.5	2
412	Xanthine Oxidase Inhibitor Treatment of Hyperuricemia., 2012, , 154-173.		2
413	The effect of age on the microarchitecture and profile of gene expression in femoral head and neck bone from patients with osteoarthritis. Bone Reports, 2020, 13, 100287.	0.2	2
414	Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes. Journal of Visualized Experiments, 2020, , .	0.2	2

#	Article	IF	CITATIONS
415	Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial. Seminars in Arthritis and Rheumatism, 2021, 51, 1218-1223.	1.6	2
416	Do Serum Urate–associated Genetic Variants Influence Gout Risk in People Taking Diuretics? Analysis of the UK Biobank. Journal of Rheumatology, 2020, 47, 1704-1711.	1.0	2
417	Regular preâ€admission urateâ€lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nationâ€wide populationâ€based cohort study. International Journal of Rheumatic Diseases, 2022, 25, 154-162.	0.9	2
418	Age-related differences in hamstring tendon used as autograft in reconstructive anterior cruciate ligament surgery. International Orthopaedics, 2022, 46, 845.	0.9	2
419	Dietary Management of Gout: What is the Evidence?. American Journal of Medicine, 2017, 130, e37.	0.6	1
420	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. PLoS ONE, 2019, 14, e0226906.	1.1	1
421	How Footwear Is Assessed in Patient Reported Measures for People with Arthritis: A Scoping Review. PM and R, 2020, 12, 161-167.	0.9	1
422	Correspondence on †Gender disparity in authorship of guidelines and recommendations in rheumatology'. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219220.	0.5	1
423	Effects of worn and new footwear on plantar pressure in people with gout. BMC Musculoskeletal Disorders, 2021, 22, 475.	0.8	1
424	What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout. Journal of Rheumatology, 2021, 48, jrheum.210476.	1.0	1
425	Which Attributes Are Most and Least Important to Patients When Considering Gout Flare Burden Over Time? A Best-worst Scaling Choice Study. Journal of Rheumatology, 2022, 49, 213-218.	1.0	1
426	More allopurinol is needed to get gout patients $< 0.36$ mmol/l: a gout audit in the form of a before-after trial. Journal of Primary Health Care, 2009, 1, 315-8.	0.2	1
427	Foot involvement in systemic lupus erythematosus: more than joint disease?. Clinical and Experimental Rheumatology, 2017, 35, 550.	0.4	1
428	271.â€ $f$ PLANTAR PRESSURE PATTERNS IN PEOPLE WITH GOUT AND DIABETES GOUT AND DIABETES. Rheumatology, 2017, 56, .	0.9	0
429	Reply. Arthritis and Rheumatology, 2019, 71, 1967-1968.	2.9	0
430	THU0664â€THE ABSOLUTE RISK OF CLINICALLY DIAGNOSED GOUT BY CLUSTERS OF GOUT ASSOCIATED COMORBIDITIES AND LIFESTYLE FACTORS â€" RESULTS FROM 30 YEARS FOLLOW-UP OF THE MALMÃ− PREVENTIVE PROJECT COHORT IN SOUTHERN SWEDEN., 2019,,.		0
431	FRIO670â€HOW DO GOUT-RELATED COMORBIDITIES AND LIFESTYLE FACTORS CLUSTER IN A LARGE HEALTH SURVEY OF THE GENERAL POPULATION? – RESULTS FROM THE MALMö PREVENTIVE PROJECT COHORT IN SOUTHERN SWEDEN. , 2019, , .		0
432	Imaging of Gout., 2019,, 89-100.		O

#	Article	IF	CITATIONS
433	Response to: †The reference levels of serum urate for clinically evident incident gout' by Chen and Ding. Annals of the Rheumatic Diseases, 2019, 78, e42-e42.	0.5	O
434	Reply. Arthritis and Rheumatology, 2021, 73, 544-545.	2.9	0
435	Explaining the natural course of gout to people living in the tropics. International Journal of Rheumatic Diseases, 2021, 24, 858-859.	0.9	0
436	Quality of care in people requiring hospital admission for gout in Aotearoa New Zealand: a nationwide analysis. Internal Medicine Journal, 2021, , .	0.5	0
437	Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. BMC Rheumatology, 2021, 5, 33.	0.6	0
438	Reply. Arthritis Care and Research, 2021, 73, 1699-1699.	1.5	0
439	Etiology and pathogenesis of gout. , 2015, , 1555-1568.		0
440	Impact of grouping serial journal articles by disease category: analysis of article placement order in <i>ARD</i> 2013–2019. Annals of the Rheumatic Diseases, 2021, 80, 545-546.	0.5	0
441	Is repeat serum urate testing superior to a single test to predict incident gout over time?. PLoS ONE, 2022, 17, e0263175.	1.1	0
442	New urate-lowering therapies in Aotearoa New Zealand: a response to Dr Lance Gravatt's letter on benzbromarone hepatotoxicity. New Zealand Medical Journal, 2013, 126, 120-3.	0.5	0
443	Urate testing in gout: why, when and how. New Zealand Medical Journal, 2015, 128, 65-8.	0.5	0
444	Development of a radiographic scoring system for new bone formation in gout. Arthritis Research and Therapy, 2021, 23, 296.	1.6	0
445	New advances in crystal arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101733.	1.4	0
446	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. , 2019, 14, e0226906.		0
447	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey., 2019, 14, e0226906.		0
448	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. , 2019, 14, e0226906.		0
449	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey., 2019, 14, e0226906.		0
450	Involving people with lived experience as partners in musculoskeletal research – lessons from a survey of Aotearoa/New Zealand musculoskeletal researchers. Journal of Orthopaedic and Sports Physical Therapy, 2022, , 1-15.	1.7	0

#	Article	IF	CITATIONS
451	An evaluation of podiatry service use for people with inflammatory rheumatic diseases: a review of a rheumatology podiatry clinic in Aotearoa New Zealand. Journal of Foot and Ankle Research, 2022, 15, 36.	0.7	O
452	Pharmacist knowledge of gout management: impact of an educational intervention. BMC Rheumatology, 2022, 6, .	0.6	0